Thousands of women who received textured breast implants are now pursuing legal claims against Allergan after developing BIA-ALCL, a rare but serious cancer linked to the company’s BIOCELL product line. Roughly 1,456 lawsuits are currently pending in a federal multidistrict litigation in New Jersey, with the first bellwether trial scheduled for June 15, 2026. No settlement has been reached yet, but the litigation is advancing through discovery and mediation, and the outcome of those initial trials will likely shape the future of every claim in the docket. BIA-ALCL — breast implant-associated anaplastic large cell lymphoma — is not breast cancer.
It is a rare type of non-Hodgkin lymphoma that develops in the scar tissue and fluid surrounding a breast implant, and 96% of FDA-reported cases have involved textured implants specifically. The FDA has tracked 1,380 cases since 2011 among the approximately 3.5 million U.S. women with breast implants, along with 64 reported deaths. Those numbers almost certainly undercount the actual toll, given the well-documented gaps in medical device adverse event reporting. This article covers what BIA-ALCL is and who is most at risk, the Allergan recall that triggered the litigation wave, where the MDL stands today, what plaintiffs need to prove, and what to consider before filing a claim.
Table of Contents
- What Is BIA-ALCL and Why Is It at the Center of Breast Implant Lawsuits?
- The Allergan BIOCELL Recall and What It Revealed
- Inside the MDL — How the Allergan Breast Implant Litigation Works
- What Plaintiffs Must Prove in a BIA-ALCL Lawsuit
- Symptoms, Diagnosis, and the Statute of Limitations Problem
- The 456 Confirmed U.S. Cases and What the Numbers Actually Mean
- What Happens After the First Bellwether Trial
- Conclusion
- Frequently Asked Questions
What Is BIA-ALCL and Why Is It at the Center of Breast Implant Lawsuits?
BIA-ALCL typically presents as a late-onset fluid collection around the implant, often appearing as sudden swelling or pain in one breast years after surgery. The median time from implant placement to diagnosis is about nine years, though cases have been documented as early as one year and as late as 22 years post-implantation. Because the symptoms can mimic common post-surgical complications like seromas, diagnosis is frequently delayed — a fact that has complicated both treatment outcomes and the legal claims surrounding the disease. The overwhelming connection to textured implants is what makes this litigation viable. Textured implants have a roughened surface designed to keep the implant in place and reduce capsular contracture.
But that same texture appears to provoke a chronic inflammatory response in some patients that can eventually trigger lymphoma. The FDA found that the risk was six times higher with Allergan’s BIOCELL textured implants compared to other textured implants on the market. That disparity is central to the legal theory: plaintiffs argue this was not simply an unavoidable risk of all implants, but a specific defect in Allergan’s product and manufacturing process. Risk estimates vary, but the American Society of Plastic Surgeons places the likelihood of developing BIA-ALCL somewhere between 1 in 3,817 and 1 in 30,000 for women with textured implants. That range is wide enough to generate real debate about how aggressively to screen asymptomatic patients, and it is narrow enough to establish that the risk is far from trivial for a device that millions of women carry in their bodies.
The Allergan BIOCELL Recall and What It Revealed
In July 2019, allergan voluntarily recalled all BIOCELL textured breast implants and tissue expanders worldwide, acting at the FDA’s request. The recall came after years of accumulating adverse event reports and mounting international pressure — France and several other countries had already pulled the products from their markets. By the time Allergan acted, the data was damning: 85% of all reported BIA-ALCL cases — 1,079 out of 1,264 at the time of the most recent data compilation — involved an Allergan implant. The recall did not, however, mean that women with existing BIOCELL implants were advised to have them removed. The FDA’s position was that asymptomatic women should not rush to explant surgery, which carries its own risks including infection, scarring, and anesthesia complications.
This created a painful limbo for hundreds of thousands of women: they were told their implant had been pulled from the market due to cancer risk, but also told not to necessarily do anything about it. Many chose explant surgery anyway, and the cost and physical toll of those procedures form a significant portion of the damages claimed in the litigation. It is worth noting that a small number of BIA-ALCL cases have involved smooth implants, though the FDA and medical literature consistently point to textured surfaces as the primary risk factor. If you have smooth implants and are experiencing unusual symptoms — persistent swelling, pain, lumps, or asymmetry — the guidance is still to consult a physician, but the statistical risk profile is substantially different. The lawsuits are overwhelmingly focused on textured implants, and Allergan’s BIOCELL line in particular.
Inside the MDL — How the Allergan Breast Implant Litigation Works
The federal lawsuits against Allergan have been consolidated into a multidistrict litigation, MDL-2921, in the U.S. District Court for the District of New Jersey. MDL consolidation is standard for mass tort cases involving a common defendant and overlapping factual questions — it allows one judge to manage pretrial proceedings efficiently rather than having hundreds of judges duplicate the same discovery battles. As of recent counts, approximately 1,456 individual cases are pending in the MDL. The litigation is now in its bellwether phase, which is the stage where a small number of representative cases are prepared for trial to test how juries respond to the evidence. Six bellwether cases have been selected, and fact discovery in all six was scheduled for completion by February 6, 2026.
Pretrial disclosures — including deposition designations and trial exhibit lists — are due by April 22, 2026. The first bellwether trial, involving a surgical explant case, is set for June 15, 2026, with five additional cases expected to follow. Bellwether verdicts do not directly bind the other cases in the MDL, but they carry enormous practical weight. A plaintiff verdict with a large damages award will pressure Allergan toward a global settlement. A defense verdict, or a series of mixed results, could reduce settlement values or encourage Allergan to fight individual cases. For plaintiffs waiting in the docket, the bellwether outcomes will likely determine whether they see meaningful compensation and how quickly.
What Plaintiffs Must Prove in a BIA-ALCL Lawsuit
The legal claims against Allergan generally fall into four categories: product liability, failure to warn, negligence, and manufacturing defects. The core allegation across all of them is that Allergan knew or should have known about the link between its textured implants and BIA-ALCL and failed to adequately warn patients and their doctors. Internal company documents, regulatory correspondence, and the timeline of adverse event reports will be critical evidence at trial. Failure-to-warn claims are often the strongest in medical device litigation because they do not require proving that the device was inherently defective in a traditional engineering sense — only that the manufacturer did not provide adequate information about known risks.
Plaintiffs will argue that Allergan had access to safety signals for years before the 2019 recall and chose to downplay or obscure them. Allergan’s defense will likely center on the argument that BIA-ALCL was a newly understood phenomenon, that the company disclosed what it knew when it knew it, and that the FDA — which approved the products — bears some responsibility for the regulatory framework. The tradeoff for individual plaintiffs is between joining the MDL, which offers strength in numbers and shared litigation costs, versus filing in state court, where local juries and different procedural rules might offer advantages depending on the jurisdiction. Most attorneys handling these cases recommend the MDL path for efficiency, but women diagnosed with BIA-ALCL in states with particularly plaintiff-friendly tort laws may have strategic reasons to stay out of the federal consolidation.
Symptoms, Diagnosis, and the Statute of Limitations Problem
One of the most significant legal complications in BIA-ALCL cases is the statute of limitations. Because the disease can take nearly a decade to develop — and because early symptoms are easily mistaken for benign complications — many women do not receive a diagnosis until years after they might otherwise be time-barred from filing suit. Most states apply a “discovery rule” that starts the clock when the plaintiff knew or should have known about the injury and its connection to the implant, rather than when the implant was placed. But the specifics vary enormously by state, and waiting too long after a diagnosis can still be fatal to a claim. Women with textured breast implants should be aware of the warning signs: sudden swelling in one breast (especially years after surgery), persistent pain, lumps near the implant, or changes in breast shape.
The standard diagnostic pathway involves ultrasound to detect fluid collection, followed by fine needle aspiration of the fluid and testing for CD30-positive cells, which is the hallmark of ALCL. Early detection matters enormously for both health outcomes and legal claims — BIA-ALCL caught at an early stage is usually treatable with implant removal and capsulectomy, while advanced cases may require chemotherapy or radiation. A critical limitation to understand: not every woman who has had a textured implant and experienced complications will have a viable BIA-ALCL lawsuit. The litigation is specifically about the cancer, not about capsular contracture, rupture, or breast implant illness more broadly. Some firms have cast a wide net in their advertising, but the actual legal claims require a confirmed or strongly suspected BIA-ALCL diagnosis. Women experiencing other implant-related problems may have separate legal options, but they fall outside the scope of MDL-2921.
The 456 Confirmed U.S. Cases and What the Numbers Actually Mean
The American Society of Plastic Surgeons has tracked 456 suspected or confirmed BIA-ALCL cases in the United States, while the FDA’s broader database includes 1,380 medical device reports. The gap between those numbers reflects the messy reality of adverse event tracking — the FDA database includes international reports, duplicate reports, and cases at varying stages of confirmation. Neither number should be treated as a precise census of the disease.
Actual incidence is almost certainly higher than either figure suggests, because BIA-ALCL can be misdiagnosed, unreported, or attributed to other causes. The 64 deaths reported to the FDA underscore that this is not merely a surgical inconvenience. While BIA-ALCL caught early has a favorable prognosis, delayed diagnosis or aggressive disease can be fatal. For the litigation, each death represents not only a wrongful death claim with potentially significant damages but also a data point that undermines any defense argument that the risk was too rare to warrant stronger warnings.
What Happens After the First Bellwether Trial
The June 2026 trial date will be the most consequential moment in this litigation since the 2019 recall. If the jury finds in favor of the plaintiff and awards substantial damages, it will create immediate settlement pressure. Allergan’s parent company, AbbVie, has the financial resources to settle a mass tort of this scale, but corporate defendants rarely move toward global resolution until they have seen how trial evidence actually plays with a jury. The five additional bellwether cases waiting behind the first will further clarify the range of outcomes.
Looking ahead, the mediation sessions that were scheduled for late 2025 suggest both sides have at least explored the possibility of a negotiated resolution. Whether those talks produce results will depend heavily on what happens at trial. For women currently considering whether to file, the window remains open — but the statute of limitations question makes delay risky. The practical advice from most plaintiff attorneys is straightforward: if you have a BIA-ALCL diagnosis linked to a textured implant, consult a lawyer now rather than waiting to see how the bellwether trials resolve.
Conclusion
The Allergan BIA-ALCL breast implant litigation is approaching a critical phase. With roughly 1,456 cases consolidated in federal court, bellwether discovery wrapping up, and the first trial set for June 2026, the next several months will determine whether this MDL moves toward a global settlement or a prolonged series of individual trials. The core facts are not in serious dispute — textured implants cause BIA-ALCL in some patients, Allergan’s BIOCELL products were responsible for a vastly disproportionate share of cases, and the company recalled the product only after sustained regulatory pressure.
For women affected by BIA-ALCL, the priority should be medical treatment first and legal action second — but not too far second. Statutes of limitations vary by state, and the discovery rule only protects plaintiffs who act within a reasonable time after diagnosis. Anyone with a confirmed or suspected BIA-ALCL diagnosis connected to a textured breast implant should consult with an attorney experienced in medical device litigation to understand their options before the legal window closes.
Frequently Asked Questions
What is BIA-ALCL and is it the same as breast cancer?
No. BIA-ALCL is a rare type of non-Hodgkin lymphoma, not breast cancer. It develops in the scar tissue and fluid surrounding a breast implant rather than in the breast tissue itself. It is most commonly associated with textured implants and typically presents as late-onset swelling.
How long after getting breast implants can BIA-ALCL develop?
The median time from implant placement to BIA-ALCL diagnosis is approximately nine years, but cases have been reported as early as one year and as late as 22 years after surgery. There is no point at which the risk definitively drops to zero for women with textured implants still in place.
Were all textured breast implants recalled?
No. Only Allergan’s BIOCELL textured breast implants and tissue expanders were recalled in July 2019. Other manufacturers’ textured implants remain on the market, though they carry their own BIA-ALCL risk at lower rates. The FDA found that BIOCELL products posed a risk six times higher than other textured implants.
Has there been a settlement in the Allergan breast implant lawsuit?
No settlement has been reached as of early 2026. The litigation is in the bellwether phase, with the first trial scheduled for June 15, 2026. Mediation sessions were held in late 2025, but no resolution has been publicly announced.
Can I still file a BIA-ALCL lawsuit?
Potentially, yes. The statute of limitations varies by state, and most jurisdictions apply a discovery rule that starts the clock when you were diagnosed or should reasonably have known about your condition. However, waiting too long after diagnosis can forfeit your right to file. Consult a medical device attorney promptly after any BIA-ALCL diagnosis.
Do I need to have my implants removed to file a lawsuit?
Not necessarily, but most BIA-ALCL treatment involves explant surgery and capsulectomy. Whether you have had the implants removed or not, a confirmed or strongly suspected diagnosis of BIA-ALCL is the foundation of a legal claim in the current MDL.